The current stock price of KNW is 2.14 USD. In the past month the price decreased by -19.25%. In the past year, price increased by 397.67%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.01 | 217.03B | ||
| ISRG | INTUITIVE SURGICAL INC | 67.03 | 204.60B | ||
| BSX | BOSTON SCIENTIFIC CORP | 32.59 | 142.51B | ||
| SYK | STRYKER CORP | 26.94 | 135.66B | ||
| BDX | BECTON DICKINSON AND CO | 13.6 | 55.98B | ||
| IDXX | IDEXX LABORATORIES INC | 54.57 | 54.95B | ||
| EW | EDWARDS LIFESCIENCES CORP | 33.58 | 50.07B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 18.17 | 37.99B | ||
| RMD | RESMED INC | 24.69 | 35.68B | ||
| DXCM | DEXCOM INC | 36.25 | 26.30B | ||
| PODD | INSULET CORP | 63.2 | 20.32B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11.15 | 17.88B |
Know Labs, Inc. engages in the development, marketing, and sale of a photonics technology. The company is headquartered in Seattle, Washington and currently employs 7 full-time employees. The company went IPO on 2006-04-12. The Company’s platform technology uses spectroscopy to direct electromagnetic energy through a substance or material to capture a unique molecular signature. The technology is designed to be able to integrate into a variety of wearable, mobile or bench-top form factors. Its patent-pending technology makes it possible to identify and monitor analytes that could only previously be performed by invasive and/or expensive and time-consuming lab-based tests. The Company’s expected application of the technology is focused on a product marketed as a non-invasive glucose monitor. The device is designed to provide the user with accessible and affordable real-time information on blood glucose levels. Its sensor technology embodies two key components: hardware and software. The hardware component includes a sensor which both sends and receives a radio frequency signal. The Company’s wholly owned subsidiary is Particle, Inc.
KNOW LABS INC
619 Western Avenue, Suite 610
Seattle WASHINGTON US
Employees: 6
Phone: 12069031351
Know Labs, Inc. engages in the development, marketing, and sale of a photonics technology. The company is headquartered in Seattle, Washington and currently employs 7 full-time employees. The company went IPO on 2006-04-12. The Company’s platform technology uses spectroscopy to direct electromagnetic energy through a substance or material to capture a unique molecular signature. The technology is designed to be able to integrate into a variety of wearable, mobile or bench-top form factors. Its patent-pending technology makes it possible to identify and monitor analytes that could only previously be performed by invasive and/or expensive and time-consuming lab-based tests. The Company’s expected application of the technology is focused on a product marketed as a non-invasive glucose monitor. The device is designed to provide the user with accessible and affordable real-time information on blood glucose levels. Its sensor technology embodies two key components: hardware and software. The hardware component includes a sensor which both sends and receives a radio frequency signal. The Company’s wholly owned subsidiary is Particle, Inc.
The current stock price of KNW is 2.14 USD. The price increased by 3.88% in the last trading session.
KNW does not pay a dividend.
KNW has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
KNW stock is listed on the NYSE Arca exchange.
KNOW LABS INC (KNW) currently has 6 employees.
KNOW LABS INC (KNW) will report earnings on 2025-11-12, after the market close.
ChartMill assigns a technical rating of 7 / 10 to KNW. When comparing the yearly performance of all stocks, KNW is one of the better performing stocks in the market, outperforming 99.51% of all stocks.
Over the last trailing twelve months KNW reported a non-GAAP Earnings per Share(EPS) of -5.03. The EPS increased by 42.83% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -3181.63% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
5 analysts have analysed KNW and the average price target is 40.8 USD. This implies a price increase of 1806.54% is expected in the next year compared to the current price of 2.14.